MDMA-assisted psychotherapy (MDMA-AT), also known as entactogen-assisted psychotherapy, is the use of prescribed doses of MDMA or sometimes other entactogens as an adjunct to psychotherapy sessions. MDMA-assisted psychotherapy is an effective treatment for post-traumatic stress disorder (PTSD), including complex PTSD (C-PTSD). Furthermore, it is currently under investigation as a treatment for various other mental health disorders, including major depressive disorder, social anxiety in people with autism, alcohol use disorder, and mood disturbances in individuals facing life-threatening illnesses. Other entactogens that have been used besides MDMA include MDA, MMDA, and methylone.
Therapeutic effects Post-traumatic stress disorder (PTSD) is most commonly treated by cognitive behavioral therapy (particularly prolonged exposure and cognitive processing therapy), eye movement desensitization and reprocessing (EMDR), and psychodynamic psychotherapy. However, over half of these patients continue to have PTSD after completing therapy, with results from war-related PTSD being especially poor. PTSD is best treated when a patient is in the 'optimal arousal zone', in which emotions are engaged, yet not overwhelming. In this zone, four symptom clusters of PTSD are sedated:
re-experiencing avoidance negative alterations in cognition/mood alterations in arousal and reactivity Subjects with PTSD exhibit extreme emotional numbing or anxiety and struggle to remain in the optimal arousal zone during conservative therapies. Threatening interpretations of memories are reinforced when patients are in low emotional states. If traumatic memories are revisited in therapy when a patient is not within the optimal arousal state, therapy for PTSD can actually increase the patient's trauma. When used in therapy, MDMA has been reported to increase empathy, closeness between patient and therapist, relaxation, motivation to engage with therapy and introspective thought, and reduce depression and anxiety. MDMA makes it easier for a patient to stay in the optimal arousal zone by decreasing feelings of anxiety and defensiveness when revisiting traumatic memories. By increasing feelings of closeness and empathy, it can improve the patient's trust in the therapist and encourage introspective thought to reassess memories and actions. Furthermore, research suggests that treatment may improve the quality of sleep of individuals affected by PTSD-related sleep disturbances. It is believed that these factors may increase the success rate of psychotherapy. Adverse effects, which can last from a few hours to several days, include diminished appetite, anxiety, headache, jaw tightness, tinnitus, nausea, asthenia (weakness), fatigue, sinusitis, nasopharyngitis, upper respiratory tract infection, disturbance in attention, tremor, tics, dysuria, erythema, and depression.
Research In 2017, a Phase II clinical trial led to a breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). With that FDA approval, MDMA has been authorized for use in research related to psychotherapy. A large proportion of this research has been focused on treating PTSD and major depressive disorder. The research is controversial in part because recreational MDMA use has been associated with harmful effects among some users. A 2022 systematic review and meta-analysis found that MDMA-assisted psychotherapy reduced PTSD symptom severity compared to control conditions.
PTSD Multiple 2020 and 2021 systematic reviews found MDMA-assisted psychotherapy to be an effective treatment for PTSD, more than any other pharmacological-assisted psychotherapy. Published later in 2021, a phase III study indicated that MDMA-assisted therapy represents a potential breakthrough treatment for severe PTSD that merits expedited clinical evaluation. Based on this study, MDMA-assisted psychotherapy was granted breakthrough therapy designation by the FDA, a designation that indicates that there is preliminary evidence that an intervention might offer a substantial improvement over other options for a serious health condition. However, given the lack of blinding, several researchers have postulated that the results of the phase III trial might be heavily influenced by expectancy effects. There are no trials comparing MDMA-assisted psychotherapy to already existing first-line psychological treatments for PTSD which seems to attain similar or elevated symptom reduction compared with that due to MDMA-assisted psychotherapy based on indirect evidence.
Major depressive disorder There have been several studies that investigated MDMA-assisted psychotherapy as a potential treatment for major depressive disorder (MDD). An analysis of six phase II trials showed a trend toward significance, while a phase III trial reported that MDMA-assisted psychotherapy had antidepressant effects. Given that unprocessed trauma is considered a causative factor in some individuals with depression, it has been proposed that the benefit observed in PTSD trials might be applicable to MDD as well.
Other MDMA-assisted psychotherapy is currently under investigation as a treatment for various other mental health disorders, including social anxiety in people with autism, alcohol use disorder, and mood disturbances in individuals facing life-threatening illnesses. The research is controversial in part because recreational MDMA use has been associated with harmful effects among some users.
Mechanism of action
PTSD inhibits a subject's ability to respond appropriately to trauma-related stimuli. The current model of PTSD proposes that it results from amplified and uncontrolled responses from the amygdala to trauma-specific cues. Oxytocin, which is increased by MDMA, has been found to increase trust and emotional awareness and reduce amygdala responses as well as reduce coupling of the amygdala to brainstem regions associated with autonomic and behavioral characteristics of fear. It has been proposed that these effects foster memory reconsolidation by allowing the patient to access the traumatic memory while feeling detached from the sense of imminent threat. MDMA is believed to create neuroplasticity, which can help break habits associated with OCD and addiction.
History
… excerpt ends here. Continue reading the full article.



